{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:41:26Z","timestamp":1790138486878,"version":"4.0.1"},"reference-count":64,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>HLA-identical sibling donor hematopoietic cell transplant (HCT) is an established curative therapy for sickle cell disease (SCD). Although myeloablative HCT conditioning achieves a high event-free survival (EFS) in children, it carries substantial toxicity, including risks of graft-versus-host disease (GVHD), transplant-related mortality, and infertility. Nonmyeloablative conditioning with alemtuzumab, 300 cGy total body irradiation, and sirolimus has demonstrated tolerability as a curative approach in adults with SCD. We conducted a multicenter, prospective clinical trial to evaluate this regimen in children and adolescents with SCD. Thirty-eight patients (aged 2.9-21.9 years; median age, 13.5 years) underwent HCT. All achieved initial engraftment; however, 7 patients (18.4%) experienced secondary graft failure between day +39 and day +391 with autologous hematologic reconstitution. One additional patient received an unconditioned second HCT. At 2 years after HCT, overall survival was 100%, and EFS was 78.9%. Among patients with engraftment, 2-year median donor myeloid chimerism was 95%, and T-cell chimerism was 75%. No patients developed acute or chronic GVHD. The median number of platelet transfusions received was 0 (interquartile range, 0-3). Patient-reported health-related quality of life remained stable early after HCT and significantly improved at 1 year. After year 2, 3 additional patients received a reduced-intensity second HCT to avert secondary graft failure. Although regimen modifications are needed to reduce graft failure risk, this nonmyeloablative approach offers a relatively low-toxicity curative option for children with SCD who have an HLA-identical sibling donor. This trial was registered at www.clinicaltrials.gov as NCT03587272.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019567","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T18:54:32Z","timestamp":1775588072000},"page":"4160-4170","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: a multicenter prospective study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4277-7523","authenticated-orcid":false,"given":"Robert Sheppard","family":"Nickel","sequence":"first","affiliation":[{"name":"1Division of Hematology, Children\u2019s National Hospital, Washington, DC"},{"name":"2Division of Blood and Marrow Transplantation, Children\u2019s National Hospital, Washington, DC"},{"name":"3Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2019-0887","authenticated-orcid":false,"given":"Allistair","family":"Abraham","sequence":"additional","affiliation":[{"name":"2Division of Blood and Marrow Transplantation, Children\u2019s National Hospital, Washington, DC"},{"name":"3Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Yueh","family":"Chiang","sequence":"additional","affiliation":[{"name":"4Department of Pediatrics, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ali","sequence":"additional","affiliation":[{"name":"5Blood and Marrow Transplant\/Cellular Therapy Program, Division of Hematology\/Oncology, The Hospital for Sick Children, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3371-2920","authenticated-orcid":false,"given":"Hemalatha G.","family":"Rangarajan","sequence":"additional","affiliation":[{"name":"6Department of Pediatric Hematology Oncology Blood and Marrow Transplant, Nationwide Children\u2019s Hospital, Columbus, OH"},{"name":"7Department of Pediatrics, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Chaudhury","sequence":"additional","affiliation":[{"name":"8Division of Pediatric Hematology Oncology\/Bone Marrow Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kent","sequence":"additional","affiliation":[{"name":"9Pediatric Transplant and Cellular Therapies Program, Levine Children's Hospital, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryanne","family":"Odinakachukwu","sequence":"additional","affiliation":[{"name":"2Division of Blood and Marrow Transplantation, Children\u2019s National Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyesh","family":"Kukadiya","sequence":"additional","affiliation":[{"name":"2Division of Blood and Marrow Transplantation, Children\u2019s National Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Malloy","sequence":"additional","affiliation":[{"name":"2Division of Blood and Marrow Transplantation, Children\u2019s National Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"10Division of Biostatistics, Children\u2019s National Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0491-4980","authenticated-orcid":false,"given":"Steven J.","family":"Hardy","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Children\u2019s National Hospital, Washington, DC"},{"name":"3Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC"},{"name":"11Department of Psychiatry and Behavioral Sciences, George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.T.","family":"Guilcher","sequence":"additional","affiliation":[{"name":"12Section of Pediatric Hematology, Oncology and Bone Marrow Transplant, University of Calgary Cumming School of Medicine, Alberta Children\u2019s Hospital, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"9861","key":"2026062308474144900_bib1","first-page":"142","article-title":"Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates","volume":"381","author":"Piel","year":"2013","journal-title":"The Lancet (British edition)"},{"key":"2026062308474144900_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-3-319-06713-1_9","article-title":"Clinical manifestations of sickle cell anemia: infants and children","author":"Nickel","year":"2016","journal-title":"Sickle Cell Anemia"},{"issue":"11","key":"2026062308474144900_bib3","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/pbc.25608","article-title":"Survival among children and adults with sickle cell disease in Belgium: benefit from hydroxyurea treatment","volume":"62","author":"L\u00ea","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"17","key":"2026062308474144900_bib4","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease","volume":"115","author":"Quinn","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2026062308474144900_bib5","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ajh.25799","article-title":"Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: the PUSH study","volume":"95","author":"Nouraie","year":"2020","journal-title":"Am J Hematol"},{"issue":"4 suppl","key":"2026062308474144900_bib6","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S","volume":"38","author":"Hassell","year":"2010","journal-title":"Am J Prev Med"},{"issue":"11","key":"2026062308474144900_bib7","doi-asserted-by":"crossref","first-page":"e1915374","DOI":"10.1001\/jamanetworkopen.2019.15374","article-title":"Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease","volume":"2","author":"Lubeck","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"9","key":"2026062308474144900_bib8","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/ajh.25202","article-title":"Clustering of end-organ disease and earlier mortality in adults with sickle cell disease: a retrospective-prospective cohort study","volume":"93","author":"Chaturvedi","year":"2018","journal-title":"Am J Hematol"},{"issue":"13","key":"2026062308474144900_bib9","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/bloodadvances.2022009202","article-title":"Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries","volume":"7","author":"Jiao","year":"2023","journal-title":"Blood Adv"},{"key":"2026062308474144900_bib10","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2022.282098","article-title":"Severity and burden of sickle cell disease in France: a nationwide realworld study","author":"Brousse","year":"2023","journal-title":"Haematologica"},{"issue":"2","key":"2026062308474144900_bib11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-148-2-200801150-00004","article-title":"Daily assessment of pain in adults with sickle cell disease","volume":"148","author":"Smith","year":"2008","journal-title":"Ann Intern Med"},{"issue":"2","key":"2026062308474144900_bib12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/ajh.21905","article-title":"Health-related quality of life in adults with sickle cell disease (SCD): a report from the Comprehensive Sickle Cell Centers Clinical Trial Consortium","volume":"86","author":"Dampier","year":"2011","journal-title":"Am J Hematol"},{"issue":"11","key":"2026062308474144900_bib13","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2026062308474144900_bib14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJM199608083350601","article-title":"Bone marrow transplantation for sickle cell disease","volume":"335","author":"Walters","year":"1996","journal-title":"N Engl J Med"},{"issue":"12","key":"2026062308474144900_bib15","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1056\/NEJM198409203111207","article-title":"Bone-marrow transplantation in a patient with sickle-cell anemia","volume":"311","author":"Johnson","year":"1984","journal-title":"N Engl J Med"},{"key":"2026062308474144900_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/adc.66.10.1195","article-title":"Bone marrow transplantation in sickle cell anaemia","author":"Vermylen","year":"1991","journal-title":"Arch Dis Child"},{"issue":"1","key":"2026062308474144900_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3324\/haematol.2018.213207","article-title":"Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France","volume":"105","author":"Bernaudin","year":"2020","journal-title":"Haematologica (Roma)"},{"issue":"1","key":"2026062308474144900_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2014.7192","article-title":"Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype","volume":"312","author":"Hsieh","year":"2014","journal-title":"JAMA : J Am Med Assoc"},{"issue":"8","key":"2026062308474144900_bib19","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/ajh.27360","article-title":"Azathioprine\/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: a prospective observational cohort study","volume":"99","author":"Dovern","year":"2024","journal-title":"Am J Hematol"},{"issue":"6","key":"2026062308474144900_bib20","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/ajh.27295","article-title":"Favorable outcome of non-myeloablative allogeneic transplantation in adult patients with severe sickle cell disease: a single center experience of 200 patients","volume":"99","author":"Damlaj","year":"2024","journal-title":"Am J Hematol"},{"issue":"4","key":"2026062308474144900_bib21","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjh.17311","article-title":"Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres","volume":"192","author":"Alzahrani","year":"2021","journal-title":"Br J Haematol"},{"issue":"3","key":"2026062308474144900_bib22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bbmt.2015.08.036","article-title":"Nonmyeloablative stem cell transplantation with alemtuzumab\/low-dose irradiation to cure and improve the quality of life of adults with sickle cell disease","volume":"22","author":"Saraf","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"2026062308474144900_bib23","first-page":"594.e1","article-title":"Comparison of regimens used for allogeneic matched related donor hematopoietic cell transplantation for sickle cell disease","volume":"31","author":"Prior","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"18","key":"2026062308474144900_bib24","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/bloodadvances.2021004394C","article-title":"American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation","volume":"5","author":"Kanter","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2026062308474144900_bib25","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.bbmt.2019.02.011","article-title":"Nonmyeloablative matched sibling donor hematopoietic cell transplantation in children and adolescents with sickle cell disease","volume":"25","author":"Guilcher","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"2026062308474144900_bib26","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2352-3026(17)30196-5","article-title":"Immunohaematological complications in patients with sickle cell disease after haemopoietic progenitor cell transplantation: a prospective, single-centre, observational study","volume":"4","author":"Allen","year":"2017","journal-title":"Lancet Haematol"},{"issue":"12","key":"2026062308474144900_bib27","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ajh.24183","article-title":"Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies","volume":"90","author":"King","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"2026062308474144900_bib28","doi-asserted-by":"crossref","first-page":"e32121","DOI":"10.1002\/pbc.32121","article-title":"Inflammatory bowel disease following allogeneic hematopoietic cell transplant for sickle cell disease","volume":"73","author":"Rowland","year":"2026","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"2026062308474144900_bib29","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41409-022-01749-9","article-title":"CD34-selected stem cell boost as therapy for late graft rejection following allogeneic transplantation for sickle cell disease","volume":"57","author":"Rangarajan","year":"2022","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"2026062308474144900_bib30","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.25401","article-title":"Bone marrow transplantation for adolescents and young adults with sickle cell disease: results of a prospective multicenter pilot study","volume":"94","author":"Krishnamurti","year":"2019","journal-title":"Am J Hematol"},{"issue":"7","key":"2026062308474144900_bib31","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/bmt.2014.84","article-title":"Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease","volume":"49","author":"Bhatia","year":"2014","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"2026062308474144900_bib32","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.bbmt.2015.01.015","article-title":"Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial","volume":"21","author":"Horan","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"2026062308474144900_bib33","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbmt.2008.08.016","article-title":"Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease","volume":"14","author":"Krishnamurti","year":"2008","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"2026062308474144900_bib34","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41409-025-02601-6","article-title":"Abatacept for acute graft versus host disease prophylaxis in children with sickle cell disease patients undergoing HLA identical sibling hematopoietic stem cell transplantation","volume":"60","author":"Ibrahimova","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"2026062308474144900_bib35","first-page":"826.e1","article-title":"Impact of abatacept inclusive graft-versus-host disease prophylaxis in pediatric stem cell transplantation for hemoglobinopathy","volume":"31","author":"Shah","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"5","key":"2026062308474144900_bib36","first-page":"305","article-title":"Two nonmyeloablative HLA-matched related donor allogeneic hematopoietic cell transplantation regimens in patients with severe sickle cell disease","volume":"31","author":"Inam","year":"2025","journal-title":"Transpl Cell Ther"},{"key":"2026062308474144900_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.70200","article-title":"RBC alloimmunization impacts pediatric sickle cell disease transplant outcomes and transfusion burden: a STAR Registry report","author":"Inam","year":"2026","journal-title":"Am J Hematol"},{"issue":"4","key":"2026062308474144900_bib38","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2015-07-655944","article-title":"Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance","volume":"127","author":"Hong","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2026062308474144900_bib39","doi-asserted-by":"crossref","first-page":"519","DOI":"10.15585\/mmwr.mm6823a2","article-title":"Sepsis attributed to bacterial contamination of platelets associated with a potential common source - multiple states, 2018","volume":"68","author":"Jones","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"2026062308474144900_bib40","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/trf.16140","article-title":"The current state of the platelet supply in the US and proposed options to decrease the risk of critical shortages","volume":"61","author":"Stubbs","year":"2021","journal-title":"Transfusion"},{"issue":"4","key":"2026062308474144900_bib41","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/pbc.24036","article-title":"Health-related quality of life (HRQL) in children with sickle cell disease and thalassemia following hematopoietic stem cell transplant (HSCT)","volume":"59","author":"Kelly","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"2026062308474144900_bib42","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-11-26","article-title":"Measuring global health-related quality of life in children undergoing hematopoietic stem cell transplant: a longitudinal study","volume":"11","author":"Rodday","year":"2013","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"2026062308474144900_bib43","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bbmt.2014.12.007","article-title":"Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease","volume":"21","author":"Bhatia","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"2026062308474144900_bib44","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/bloodadvances.2024013926","article-title":"Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease","volume":"9","author":"Walters","year":"2025","journal-title":"Blood Adv"},{"key":"2026062308474144900_bib45","doi-asserted-by":"crossref","DOI":"10.6002\/ect.2021.0392","article-title":"Gonadal status and sexual function at long-term follow-up after allogeneic stem cell transplantation in adult patients with sickle cell disease","author":"Boga","year":"2022","journal-title":"Exp Clin Transpl"},{"issue":"7","key":"2026062308474144900_bib46","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1097\/MPH.0000000000001782","article-title":"Longitudinal description of gonadal function in sickle-cell patients treated with hematopoietic stem cell transplant using alkylator-based conditioning regimens","volume":"42","author":"Elchuri","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"issue":"8","key":"2026062308474144900_bib47","doi-asserted-by":"crossref","first-page":"531.e1","DOI":"10.1016\/j.jtct.2023.05.004","article-title":"Female reproductive health outcomes after hematopoietic cell transplantation for sickle cell disease: is reduced intensity better than myeloablative conditioning?","volume":"29","author":"Meacham","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"2026062308474144900_bib48","first-page":"537","article-title":"RIC does not do the trick to prevent the high infertility risk in females with sickle cell disease after hematopoietic cell transplantation","volume":"29","author":"Nickel","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"9","key":"2026062308474144900_bib49","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.3390\/jcm11092318","article-title":"Fertility after curative therapy for sickle cell disease: a comprehensive review to guide care","volume":"11","author":"Nickel","year":"2022","journal-title":"J Clin Med"},{"issue":"6","key":"2026062308474144900_bib50","doi-asserted-by":"crossref","first-page":"e13496","DOI":"10.1111\/petr.13496","article-title":"Adolescent male fertility following reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in non-malignant disorders","volume":"23","author":"Zhao","year":"2019","journal-title":"Pediatr Transpl"},{"issue":"25","key":"2026062308474144900_bib51","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1182\/blood.2023023301","article-title":"An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease","volume":"143","author":"Kassim","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2026062308474144900_bib52","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/bjh.70093","article-title":"Granulocyte colony-stimulating factor may improve engraftment in adults with sickle cell disease undergoing non-myeloablative haematopoietic stem cell transplantation","volume":"207","author":"Zhu","year":"2025","journal-title":"Br J Haematol"},{"issue":"12","key":"2026062308474144900_bib53","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.bbmt.2017.08.038","article-title":"Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease","volume":"23","author":"Abraham","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"2026062308474144900_bib54","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3324\/haematol.2019.227561","article-title":"Extensive multilineage analysis in patients with mixed chimerism after allogeneic transplantation for sickle cell disease: insight into hematopoiesis and engraftment thresholds for gene therapy","volume":"105","author":"Magnani","year":"2020","journal-title":"Haematologica"},{"issue":"17","key":"2026062308474144900_bib55","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","article-title":"At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT","volume":"130","author":"Fitzhugh","year":"2017","journal-title":"Blood"},{"issue":"26","key":"2026062308474144900_bib56","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/blood.2018874115","article-title":"Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation","volume":"133","author":"Baker","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2026062308474144900_bib57","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/bloodadvances.2020003910","article-title":"Cumulative incidence of subsequent malignancy after allo-HCT conditioned with or without low-dose total body irradiation","volume":"6","author":"Nunez","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2026062308474144900_bib58","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.22.01203","article-title":"Secondary neoplasms after hematopoietic cell transplant for sickle cell disease","volume":"41","author":"Eapen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"23","key":"2026062308474144900_bib59","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1182\/blood.2022017960","article-title":"Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism","volume":"140","author":"Lawal","year":"2022","journal-title":"Blood"},{"issue":"13","key":"2026062308474144900_bib60","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2017-05-783233","article-title":"Increased risk of leukemia among sickle cell disease patients in California","volume":"130","author":"Brunson","year":"2017","journal-title":"Blood"},{"key":"2026062308474144900_bib61","article-title":"Long-term follow-up after mixed donor myeloid chimerism at 1 year post transplantation for sickle cell disease","author":"Guilcher","year":"2026","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"2026062308474144900_bib62","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute myeloid leukemia case after gene therapy for sickle cell disease","volume":"386","author":"Goyal","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"2026062308474144900_bib63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ajh.26741","article-title":"Lovo-cel gene therapy for sickle cell disease: treatment process evolution and outcomes in the initial groups of the HGB-206 study","volume":"98","author":"Kanter","year":"2023","journal-title":"Am J Hematol"},{"issue":"2","key":"2026062308474144900_bib64","doi-asserted-by":"crossref","first-page":"e31448","DOI":"10.1002\/pbc.31448","article-title":"Systemic inflammatory response post alemtuzumab and low-dose total body irradiation in pediatric patients with sickle cell disease: a case series","volume":"72","author":"Chok","year":"2025","journal-title":"Pediatr Blood Cancer"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/12\/4160\/2526570\/blooda_adv-2025-019567-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/12\/4160\/2526570\/blooda_adv-2025-019567-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:53:48Z","timestamp":1782219228000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/12\/4160\/567603\/Nonmyeloablative-HLA-identical-sibling-transplant"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":64,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,6,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019567","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,23]]},"published":{"date-parts":[[2026,6,10]]}}}